Pre-clinical Development of a Novel Second Generation Chemotherapeutic for Cancer Therapy [ 2012 - 2014 ]

Research Grant

Researchers: Prof Des Richardson (Principal investigator) ,  Dr David Lovejoy ,  Prof John Mills

Brief description Cancer cells have a high iron requirement for DNA synthesis and many clinical trials have shown that iron chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of the iron chelator, Triapine, into widespread NCI clinical trials. In this NHMRC Development Grant, we will perform toxicological studies to enable clinical trials of our most potent and selective anti-cancer agent to commence.

Funding Amount $AUD 584,907.21

Funding Scheme Development Grants

Notes Development Grant